SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following its recent FDA approval for Aqvesme, positioning it as the sole approved treatment for alpha- and beta-thalassemia. This significant regulatory milestone is sparking community discussion around its market potential and expected impact, driving considerable trading activity despite past investor concerns regarding other pipeline developments.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as the community discusses its approaching max circulating supply, anticipating a significant supply shock and potential for upward movement. This bullish outlook is heavily contested by concerns over the Compound Foundation's financial runway and ongoing governance challenges, leading to highly polarized views on its future in the decentralized finance landscape. Many compare its trajectory unfavorably to competitors like AAVE, highlighting deep divisions within the community.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending following the FDA approval of YARTEMLEA, its first-in-class therapy for transplant-associated thrombotic microangiopathy (TA-TMA). Investors are celebrating this significant milestone, anticipating substantial upside potential given the drug's unique market position and the company's strengthened financial outlook from a major licensing deal. The community is actively discussing a potential re-rating of the stock and speculation around a possible acquisition.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is currently trending as a leading bank stock, driven by significant regulatory progress and ongoing strategic initiatives, including a major wealth management partnership and advancements in digital assets. The community is actively discussing its substantial price appreciation and perceived undervaluation, while some caution about its rapid ascent and overbought technical indicators.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is seeing a significant surge and high trading volume following the announcement that Sanofi will acquire the company for $15.50 per share in cash to bolster its adult immunization portfolio. While many long-term shareholders are celebrating much-anticipated gains, a notable segment of the community expresses disappointment, believing the offer undervalues the company given its vaccine assets and prior market discussions. This acquisition brings to a head ongoing conversations about the company's valuation and strategic direction.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO (RAVE CRYPTO) is a trending topic, primarily fueled by a news report detailing Trumps World Liberty Financial's integration of Aster Trade into its USD1 expansion, coinciding with the RAVE token achieving a record high. The community is actively discussing its breakout potential, with many expressing enthusiasm to participate in what they view as a significant rally and a potential for substantial upside, noting considerable recent trading volume.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending following its recent public offering to fund a demonstration plant, significant technical validation from its Shell GameChanger graduation and successful steam-cracking trials, and a new collaboration in Mexico. While proponents see these as strong steps towards commercialization in a vast clean technology market, skeptics question the company's valuation and the long-term economic viability of its pre-revenue process, fueling a strong debate across the community.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is actively trending as the community weighs a proposed tokenomics redesign aimed at transitioning from inflationary staking rewards to a revenue-based model, hoping to enhance long-term value. While some anticipate a crypto-wide rally and see current prices as a buying opportunity, many remain concerned about its historical price performance and ongoing comparisons to newer, high-throughput, compliance-focused blockchain infrastructure.

Philip Morris International, Inc. is a holding company, which engages in the business of delivering a smoke-free future and evolving a portfolio for the long term to include products outside of the tobacco and nicotine sector. It operates through the following geographical segments: Europe Region (Europe), South and Southeast Asia, Commonwealth of Independent States, Middle East, and Africa Region (SSEA, CIS, and MEA), East Asia, Australia, and PMI Duty Free Region (EA, AU, and PMI DF), and Americas Region (Americas). The Europe segment includes all the European Union countries, Switzerland, the United Kingdom, Ukraine, Moldova, and Southeast Europe. The SSEA, CIS, and MEA segment focuses on South and Southeast Asia, the African continent, the Middle East, Turkey, Israel, Central Asia, Caucasus, and Russia. The EA, AU, and PMI DF segment is involved in the consolidation of international duty-free business with East Asia and Australia. The Americas segment is comprised of the United States, Canada, and Latin America. The company was founded by Philip Morris in 1847 and is headquartered in Stamford, CT.

Philip Morris International Inc

Philip Morris International is gaining significant traction from its rapidly expanding smoke-free product portfolio, particularly IQOS and ZYN, driving strong financial performance. The company's strategic pivot away from traditional combustibles, coupled with recent regulatory news regarding expedited nicotine pouch reviews, is fueling market conversation. Community discussion highlights PM as a defensive growth opportunity, though some debate the sustainability of ZYN's momentum and the market's reaction to earnings reports.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT CRYPTO is actively trending with heightened discussion and trading volume, significantly fueled by its recent listing on Robinhood and strategic backing by Coinbase's Base app. Community sentiment is deeply divided, with many anticipating a substantial price rally due to these developments, while a vocal segment expresses skepticism over perceived "rug pulls," token unlocks, and concerns about leadership, intensifying the debate around its market trajectory. Investors are weighing its potential as a leading perp DEX against rivals, highlighting a dynamic and contentious trading environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PROF has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the Cum Laude award for his presentation titled “CAPTAIN Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (TULSA) Versus Robotic Radical Prostatectomy” at the 2025 Radiological Society of North America (RSNA) Annual Meeting, yesterday in Chicago 
 
https://biotuesdays.com/2025/12/05/stanfords-dr-ghanouni-receives-cum-laude-award-for-rsna-presentation-on-captain-trial-of-tulsa-v-robotic-radical-prostatectomy/

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body

BioTuesdays

Stanford's Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy - BioTuesdays

StockTwits Web

Profound Medical Corp

 has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the Cum Laude award for his presentation titled “CAPTAIN Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (TULSA) Versus Robotic Radical Prostatectomy” at the 2025 Radiological Society of North America (RSNA) Annual Meeting, yesterday in Chicago 
 


@BioTuesdays  
Is this new advertising/marketing team going to run with this report? Are they going to let potential patients know this?  Where on the website can potential TULSA Pro patients find a provider? The website is terrible, old, does not show all the places they can go to. and has functioning issues that are still there, making it hard to find a provider!  
You don&#39;t need a whole new site. Fix the part that patients need. Keep it updated. Show them how much safer this is versus robotic surgery.  
Why is this not happening?

  
Is this new advertising/marketing team going to run with this report? Are they going to let potential patients know this?  Where on the website can potential TULSA Pro patients find a provider? The website is terrible, old, does not show all the places they can go to. and has functioning issues that are still there, making it hard to find a provider!  
You don't need a whole new site. Fix the part that patients need. Keep it updated. Show them how much safer this is versus robotic surgery.  
Why is this not happening?